An observational study in Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma, Multiple Myeloma Progression and Multiple Myeloma Refractory, sponsored by Odense University Hospital. Not yet recruiting at 3 sites in Denmark. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-10-23.
Sponsored by Odense University Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 124 studies in Multiple Myeloma with a site in Denmark — 22 open to participants now, 44 under way, 26 of them phase 3. Multiple Myeloma · Denmark.
Among the 124 studies in Multiple Myeloma with a site in Denmark, this one is the 9th largest by planned enrollment of the 14 observational ones that give a count, is one of 8 that started in 2026, is one of 14 observational ones, reaches primary completion later than 19 of the 43 other live ones, and was the 118th registered.
3,764 studies on the registry are indexed under Multiple Myeloma; 768 are open to participants now.
Browse Multiple Myeloma studies →22 of the 124 studies in Multiple Myeloma with a site in Denmark are open now. Recruiting first, the newest first:
AstraZeneca · Sites in Denmark, United States, Australia and 15 more countries
Ages 18–130
CSL Behring · Sites in Denmark, United States, Belgium and 8 more countries
Ages 18+
AstraZeneca · Sites in Denmark, United States, Australia and 12 more countries
Ages 18+
Hoffmann-La Roche · Sites in Denmark, United States, Australia and 15 more countries
Ages 18+
Takeda · Sites in Denmark, United States, Australia and 14 more countries
Ages 18+
A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →
Of the 583 Multiple Myeloma studies recruiting now, 428 (73%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.
This study: 18 Years to 100 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
124 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 25 · Phase 2 41 · Phase 3 48 · Phase 4 2
First in 2000; this study’s year is marked. 8 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 50 is below the median of 150 across 486 observational studies indexed under Multiple Myeloma.
Median enrollment 179 across the 110 interventional studies, 102 across the 14 observational. Of the 73 that completed or were terminated, 35 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
73 of 124 have an industry lead sponsor. The 10 most frequent:
Odense University Hospital is the lead sponsor of 480 studies on the registry; 111 are open to participants now.
Odense University Hospital has 6 studies filed under Multiple Myeloma — fewer than ten, so there is no comparison to draw.
8 of the studies in Multiple Myeloma with a site in Denmark that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03319667Phase 3SanofiA Study to Investigate the Clinical Benefit of Isatuximab in Combination With Bortezomib, Lenalidomide and Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant | 2027-04-05 |
| NCT03844048Phase 3AbbVieAn Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial | 2027-08 |
| NCT04975997Phase 3CelgeneOpen-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) | 2027-11-16 |
| NCT06505369North Estonia Medical CentreBispecific T-cell Redirectors as Part of First Line Treatment in Transplant Eligible Multiple Myeloma Patients | 2026-11 |
| NCT03989414CelgeneA Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM) | 2026-11-30 |
Add all 8 to your calendar (.ics) → With an account.
Among the 124 studies in Multiple Myeloma with a site in Denmark, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Treatment for blood cancers has improved significantly, and more patients are now living longer. However, these treatments are often intensive and long-lasting, and many patients experience serious side effects and symptoms. As more patients require ongoing treatment and long-term care, the demand for haematology services is increasing.
Home-based treatment is expected to play an increasingly important role in the future. It can support more patient-centred care, help patients maintain their everyday lives, improve quality of life, and reduce pressure on hospitals. Despite these benefits, some patients are either not eligible for home-based treatment or choose to decline it. The reasons for this are not yet well understood.
This study combines quantitative data-such as medical information, sociodemographic characteristics, and questionnaire responses about quality of life and health literacy-with qualitative interviews involving patients, relatives, and healthcare professionals. The aim is to identify barriers and differences between patients, and to better understand why some patients opt out of or are unable to participate in home-based treatment.
The findings will help support the development of more inclusive and patient-centred care models, ensure more equal access to home-based treatment, and improve support for socially vulnerable patients. The results will be shared with patients and families through patient organisations, with hospitals through the Treat@Home programme, and at national and international conferences.
Background Advances in treatment have improved survival for patients with hematologic malignancies, yet these patients remain at risk of severe complications and a high symptom burden.
As more patients require treatment and long-term care, the demand for hematologic services continues to grow. Home-based treatment is therefore expected to play an increasingly important role, with the potential to enhance patient-centered care, support daily life, improve quality of life, and reduce hospital burden. However, a proportion of patients do not meet the eligibility requirements for home-based treatment, and others choose to decline this option despite being offered the opportunity. Understanding the characteristics, experiences, and perspectives of these patients is essential for developing equitable, patient-centered approaches to treatment delivery and ensuring that home-based care models do not inadvertently exacerbate health disparities. Understanding this knowledge gap is crucial. These patients often undergo long, intensive treatment, and socially vulnerable patients may face additional practical, emotional, or social challenges. Home-based treatment could provide flexibility and support to reduce such inequalities. Without insight into why some patients decline or are ineligible for home-based treatment, there is a risk that these models will primarily serve more resourceful patients, potentially reinforcing health disparities.
The overall aim of this mixed methods study is to investigate reasons for declining or being deemed ineligible for home-based treatment among patients with hematologic malignancies, their caregivers and healthcare professionals.
This will be addressed with the following questions:
Design A mixed methods design will be applied, using quantitative and qualitative data. The qualitative study will apply interpretive description as a methodological framework. The qualitative and quantitative data will be merged, and through the mixed methods design, our aim is to converge two data sets and draw meta-inferences to gain deeper insights into the complexity of barriers to home-based treatment.
Participants In the quantitative sub-study, all patients from the Department of Hematology at Odense University Hospital (OUH) and ZUH who are enrolled in the two Treat@Home studies will be invited to participate, including those who accept, decline, or are deemed ineligible for home-based treatment. Inclusion will occur prospectively following enrollment. The aim is to include 50 participants, with 25 recruited from each site. While a formal sample size calculation is not appropriate at this stage, this number is justified on practical and methodological grounds.
In the qualitative sub-study, patients are eligible if they are invited to the quantitative sub-study but either declined or are deemed ineligible for home-based treatment. The aim is to include 20-25 participants, a range expected to achieve thematic saturation while allowing in-depth exploration of individual narratives. The final sample size will be determined based on Malterud's concept of information power, considering interview quality and participant variation.
Data collection In the quantitative sub-study, general medical data, comorbidities (Charlson Comorbidity Index), cancer-specific data, sociodemographic data, and patient reported outcomes will be collected at time of recruitment. Patient reported outcomes include health literacy (Health Literacy Questionnaire), quality of life (European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30), and caregiver burden (Caregiver Roles and Responsibilities Scale). In the qualitative sub-study, separate semi-structured interview guides for patients, caregivers and health professionals will be developed based on the literature to define key research topics. Participants can choose to be interviewed at home, the research facility, or during a hospital visit.
Analysis In the quantitative sub-study, data will be analyzed using descriptive statistics. Numerical variables will be reported as means and medians (with ranges) and compared using Student's t-test. Categorical variables will be presented as counts and percentages. Differences between patients who accept or decline/are deemed ineligible will be assessed using appropriate tests, such as the Wilcoxon rank-sum test and Fisher's exact test. A p-value \<0.05 will be considered statistically significant.
In the qualitative sub-study, all interviews will be transcribed verbatim and analyzed using Braun and Clarke's thematic analysis framework. The six-step process includes: 1) familiarization with the data through repeated reading and listening, 2) generating meaningful units, 3) identifying initial themes, 4) reviewing themes, 5) defining and naming themes, and 6) reporting the findings. Steps 1-3 will be conducted by a trained research nurse and steps 4-5. Analyses will be performed using NVivo version 14. Ethical considerations The study will be registered with the Danish Protection Agency and Clinical Trials. Participants will receive written and verbal information, including assurances of confidentiality in line with the Helsinki Declaration, and written consent will be obtained at recruitment. Given participants' potential vulnerability, extra care will be taken to ensure voluntary participation, and they will have time to debrief and discuss their experiences.
Project feasibility This study is highly feasible due to its integration within the national Treat@Home research program, which provides established infrastructure, clinical networks, and experience. OUH and ZUH have both conducted home-based treatment studies with Daratumumab and Cytarabine, ensuring access to the target patient population and familiarity with study protocols. The research team includes experienced clinicians and researchers in hematology, patient-reported outcomes, and mixed-methods research. Recruitment is facilitated through ongoing Treat@Home studies, and the qualitative sample size is achievable using thematic saturation and information power principles. Data collection and analysis procedures are well-established, using validated instruments and software to ensure robust integration of quantitative and qualitative findings.
Limitations The mixed-methods design strengthens this study by combining quantitative and qualitative data to understand why some patients decline or are deemed ineligible for home-based treatment. Limitations include potential constraints from sample size, missing data, and recruitment challenges, particularly among socially vulnerable groups, which may introduce selection bias. The qualitative findings, while rich, may have limited transferability and depend on participants' willingness to share experiences. Despite these challenges, integrating both data types allows triangulation and nuanced insights, providing critical knowledge to guide future studies and develop interventions that promote equitable access to home-based hematology treatment.
All patients from the Department of Hematology at Odense University Hospital and Zealand University Hospital who are enrolled in the two Treat@Home studies will be invited to participate, including those who accept, decline, or are deemed ineligible for home-based treatment. We aim to include 50 participants, with 25 recruited from each site.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
- Dementia, psychotic disorders, or other cognitive impairments limiting participation.
Patients who are enrolled in one of the two Treat@Home studies will be invited to participate
Patients who are invited in one of the two Treat@Home studies but decline this invitation will be invited to participate
Patients deemed not eligible for enrollment in one of the two Treat@Home studies will be invited for enrollment
Perceptions - patient
Semi-structured interviews with patients at inclusion
Time frame: Day 1
Perception - caregivers
Semi-structured interviews with caregiver (together with patient) at inclusion
Time frame: Day 1
Perception - Healthcare staff
Focus group interview with Healthcare staff at end of study (after inclusion of all patients) in regards to barriers and possibilities in home administration
Time frame: At study completion (end of inclusion of all patients)
Biological sex
male, female
Time frame: Day 1
Patient reported outcomes
Health literacy was assessed using the Health Literacy Questionnaire (HLQ), which contains multiple domains scored on separate scales, with higher scores indicating better health literacy.
Time frame: Day 1
Patient Reported Outcome
Quality of life was assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30; scores range from 0-100, with higher functional and global health scores indicating better quality of life and higher symptom scores indicating greater symptom burden).
Time frame: Day 1
Caregiver burden
Caregiver burden was assessed using the Caregiver Roles and Responsibilities Scale (CRRS), with higher scores indicating greater caregiver burden.
Time frame: Day 1
Age
Number
Time frame: Day 1
Residents
Capital, Zealand, Southern, Middle, North
Time frame: Day 1
Distance to hospital from home address
kilometer (number)
Time frame: day 1
Urbanicity
1\. Cities (densely populated area), 2. Towns, 3. suburbs (intermediate density area), and 4. rural (thinly populated area)
Time frame: Day 1
Performance status
0, 1, 2, 3, 4
Time frame: Day 1
Hematologic diagnosis
multiple myeloma or acute myeloid leukemia
Time frame: Day 1
Diagnose subtype
IgA, IgG, IgM, Light chain, non-secretory, plasma cell, de novo, secondary, or relapsed/refractory
Time frame: Day 1
Blasts in bone marrow
Number
Time frame: Day 1
Planned treatment regime
Mono-therapy or combination
Time frame: Day 1
Previous lines of treatment
number
Time frame: Day 1
Time of diagnosis
Date
Time frame: day 1
Weight
kilogram (number)
Time frame: Day 1
Etnicity
White, Inuit, other (text)
Time frame: Day 1
Civil status
Married/cohabiting, widowed, divorced, single, other (text)
Time frame: Day 1
Number of children
Number
Time frame: Day 1
Living situation
Living with other, living alone, other
Time frame: Day 1
Educational level
Folkeskole, Gymnasie, Kort videregående uddannelse (\<3 years), Middel videregående uddannelse (3-4 years), Lang videregående uddannelse (\>4 years), Erhvervsuddannelse, or other (text)
Time frame: Day 1
Employment status
full-time, part-time, unemployed, retired, sick leave
Time frame: Day 1
Previous self-administered home-based treatment (e.g., injections or a medication pump)
yes, no
Time frame: Day 1
Smoking habits
Never, Former, Current
Time frame: Day 1
Alcohol use behaviour
Never, Former, Current
Time frame: Day 1
Regularly follow up for other illnesses than MM/AML at the hospital or with your general practitioner (at least once a month)
yes, no
Time frame: Day 1
Receive help from home care and/or visiting nurses on a daily basis
yes, no
Time frame: Day 1
Nearest relative most involved in disease
spouse, child, family member, friend, neighbor, other
Time frame: Day 1
Plan to share: Undecided — Considering sharing data upon request.
No publications or documents are linked to this record.
Start is estimated for Nov 2026; primary completion for Jun 2027, 7 months later.
Of 173 non-industry observational studies under Multiple Myeloma, half reached primary completion within 68 months of starting (the median), counting those still running; a quarter within 31. This study's planned 7 months is below that.
Counting every sponsor, half of 239 studies reached it within 57 months; a quarter within 30 and three quarters within 126.
Start moved once since we started tracking on Sep 25, 2026: Jul 2026 → Nov 2026, on Oct 23, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.